Back to results
US 2021/0173877 A1Published application
Methods of use of emulsion formulations of an nk-1 receptor antagonist
AssigneeHeron Therapeutics, Inc.
InventorsThomas B. Ottoboni, Han Han
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Claims14
A method for preventing post-operative nausea and vomiting in a subject, comprising:
- administering an injectable pharmaceutical emulsion comprising:
- a neurokinase-1 (NK-1) receptor antagonist;
- an emulsifier;
- an oil;
- a co-surfactant;
- and
- an aqueous phase,
- wherein the ratio of the emulsifier to the NK-1 receptor antagonist ranges from about 18:1 to 22:1 (wt/wt %).
5 more elements
Dependencies are inferred from the claim text.